Bone Marrow Micrometastases in Breast Cancer Patients: A Long-Term Follow-up Study
Author Information
Author(s): Annamaria Molino, Monica Giovannini, Rocco Micciolo, Alessandra Auriemma, Elena Fiorio, Antonio Santo, Gian Luigi Cetto
Primary Institution: University of Verona
Hypothesis
Does the presence of bone marrow micrometastases at the time of primary surgery correlate with disease-free and overall survival in breast cancer patients?
Conclusion
The study found no significant difference in survival between patients with and without micrometastases, but time-dependent changes in bone marrow status may have prognostic implications.
Supporting Evidence
- 54 patients relapsed and 45 died during the follow-up period.
- 31.5% of relapsing patients had a positive first bone marrow sample.
- 10-year probability of relapse-free survival was similar in patients with and without micrometastases.
- The hazard ratio for relapse was 1.87 after accounting for time-dependent changes.
Takeaway
This study looked at breast cancer patients and found that having cancer cells in the bone marrow at surgery didn't change how long they lived, but checking the bone marrow over time might give more important information.
Methodology
Patients underwent bone marrow aspiration at surgery and every 6–8 months thereafter, with analysis of disease-free and overall survival.
Limitations
The study's findings may be limited by the retrospective nature and the reliance on patient compliance for follow-up bone marrow aspirates.
Participant Demographics
125 early breast cancer patients, operable stage I and II.
Statistical Information
P-Value
0.286
Confidence Interval
90% C.I.: 0.515–0.774 for relapse-free survival; 90% C.I.: 0.569–0.820 for overall survival.
Want to read the original?
Access the complete publication on the publisher's website